Sanofi: Multiple Sclerosis, Relapsing-Remitting trials
The registry lists 10 Multiple Sclerosis, Relapsing-Remitting studies with Sanofi as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 2 4Phase 3 4Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409CompletedNCT02255656Phase 4Results posted
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabCompletedNCT00930553Phase 3Results posted
- A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple SclerosisCompletedNCT00883337Phase 3Results posted
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoCompletedNCT00548405Phase 3Results posted
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneCompletedNCT00530348Phase 3Results posted
- A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple SclerosisCompletedNCT00050778Phase 2Results posted
- Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839TerminatedNCT02306811Phase 2
- Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple SclerosisTerminatedNCT02222948Phase 2
- Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADACompletedNCT02205489Phase 4
- Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT00228163Phase 2